Compare AU
Compare AYLD vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X S&P/ASX 200 Covered Call Complex ETF (AYLD) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
AYLD | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 13 | 76 |
Median incremental investment | $1,168.50 | $640.11 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,928.88 | $1,248.00 |
Average age group | > 35 | > 35 |
Key Summary
AYLD | CURE | |
|---|---|---|
Strategy | AYLD.AX was created on 2023-01-30 by Global X. The fund's investment portfolio concentrates primarily on total market equity. The ETF currently has 76.93m in AUM and 202 holdings. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P/ASX BuyWrite Index | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | Commonwealth Bank of Australia (11.98 %) BHP Group Ltd (8.21 %) CSL Ltd (5.20 %) | Natera Inc (2.77 %) Alnylam Pharmaceuticals Inc (2.60 %) Vertex Pharmaceuticals Inc (2.58 %) |
Top 3 industries | Financials (56.05 %) Materials (16.46 %) Health Care (10.33 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | Australia (94.85 %) United States (3.09 %) New Zealand (1.58 %) | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) |
Management fee | 0.6 % | 0.45 % |
Key Summary
AYLD | CURE | |
|---|---|---|
Issuer | Global X | Global X |
Tracking index | S&P/ASX 200 Index | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 0.6 % | 0.45 % |
Price | $10.26 | $41.60 |
Size | $76.308 million | $30.458 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 4.18 % | 4.24 % |
Market | ASX | ASX |
First listed date | 31/01/2023 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
AYLD | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 13 | 76 |
Median incremental investment | $1,168.50 | $640.11 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,928.88 | $1,248.00 |
Average age group | > 35 | > 35 |
Pros and Cons
AYLD | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
AYLD | CURE |
|---|---|
Higher exposure to AU market | Lower exposure to AU market |
Lower exposure to US market | Higher exposure to US market |
Higher management fee | Lower management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |